SEATTLE, Wa., January 6, 2017 - Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces it has entered into an agreement with Amgen to further develop and commercialize Adaptive’s NGS-based clonoSEQ Assay to assess minimal residual disease (MRD) in patients with Acute Lymphoblastic Leukemia (ALL).
BREAKING NEWS FROM ADAPTIVE
Adaptive and its collaborators will present data demonstrating how immunosequencing can inform survival in patients with blood cancers at the American Society of Hematology (ASH) meeting from December 7-10, 2013.
Adaptive announced today the publication of a method to significantly improve the accuracy of next-generation immune system profiling by creating a fully validated Synthetic Immune System (SISTM) to control for any possible bias caused by the amplification method used to characterize the enormous complexity of the adaptive immune system. The SIS method, developed and validated in Adaptive’s Seattle laboratories is described in the October 25th issue of Nature Communications, and demonstrates the Company’s fundamental commitment to data quality.
Adaptive announced today that the Company has obtained a Notice of Allowance in U.S. Patent Application Serial No. 12/794,507, titled “Method of Measuring Adaptive Immunity,” exclusively licensed by Adaptive Biotechnologies from the Fred Hutchinson Cancer Research Center.
Adaptive CEO, Chad Robins, will be highlighting the companies’ pipeline of oncology diagnostics in a 30 minute presentation on October 10th at the Precision Medicine conference in NYC. Mr. Robins will focus on Adaptive’s state-of-the-art immune sequencing assays that are being used to discover and develop applications for prognosis, diagnosis, and monitoring over the life cycle of a cancer patient.
Adaptive announced results from an ovarian cancer study, conducted in collaboration with Fred Hutchinson Cancer Research Center, highlighting the even distribution of immune fighter cells (T-cells) within the tumor. The study, published online in The Journal of Pathology ahead of the print publication, demonstrated the ability of Adaptive’s immunoSEQTM assay to assess the quantity and clonality of immune system cells within a tumor at a depth and specificity made possible by next-generation sequencing.
Ultra-sensitive detection of minimal residual disease now available to more people with blood cancers
SOUTH SAN FRANCISCO, Calif. – Sequenta, Inc., today announced that the sample types eligible for analysis with its ClonoSIGHT™ minimal residual disease (MRD) test for leukemia and lymphoma have been expanded to include formalin-fixed, paraffin-embedded (FFPE) tissue and bone marrow aspirate slides. This advancement allows the test to be performed on the diagnostic samples most commonly available from pathology labs.
SOUTH SAN FRANCISCO, Calif. – Sequenta, Inc., today published results demonstrating that a combination of traditional immune assays and next-generation sequencing can be used to characterize immune responses at a level not possible using standard assays alone.
SEATTLE, WA, – Adaptive Biotechnologies Corporation CEO, Chad Robins, will join Nils Longberg, Senior Vice President Biologics Discovery, from Bristol Myers Squibb in a “fireside chat” panel at the Cancer Advance Conference at Harvard Medical School on September 19th, 2013.
Adaptive announced today that it received a $2.53 million Phase II Small Business Innovation Research award from the National Heart, Lung, and Blood Institute, a division of the NIH, to commercialize a test to measure the ability of a cancer patient’s adaptive immune system to fight infection after a cord blood transplant.
Adaptive Biotechnologies received complimentary coverage today on National Public Radio’s “Latest News in Biotech” segment with Luke Zimmerman.